Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1993 Jul;68(1):140–145. doi: 10.1038/bjc.1993.302

The prognostic value of early CA125 serum assay in epithelial ovarian carcinoma.

J Fisken 1, R C Leonard 1, M Stewart 1, G J Beattie 1, C Sturgeon 1, L Aspinall 1, J E Roulston 1
PMCID: PMC1968323  PMID: 8318405

Abstract

We examined the prognostic value of early serum CA125 assay in 58 patients with advanced epithelial ovarian cancer together with residual disease, age, tumour grade, performance status, and the presence of ascites or adhesions at primary surgery. CA125 was a highly significant predictor of both progression free and overall survival after the first cycle and throughout primary chemotherapy. After the first cycle, CA125 was by far the most significant predictor of progression free survival (P < 0.0005). At this time, CA125 was a highly significant predictor of survival (P < 0.005), but did not add to performance status (P < 0.001) in multivariate analysis. We were able to identify three statistically-distinct prognostic groups. Patients in the upper quartile, with CA125 levels greater than 450 U ml-1, had a very poor median survival of 7 months. Patients in the lower quartile, with CA125 levels less than 55 U ml-1 had a good median survival of 23 months. Those in the two interquartile groups, who had CA125 levels ranging from 58-221 U ml-1 and 228-434 U ml-1, had relatively intermediate median survival times of 16 months and 15 months respectively. Although CA125 levels provided significant prognostic information, in the majority of patients CA125 merely confirmed overall clinical impression.

Full text

PDF
140

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bast R. C., Jr, Klug T. L., St John E., Jenison E., Niloff J. M., Lazarus H., Berkowitz R. S., Leavitt T., Griffiths C. T., Parker L. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med. 1983 Oct 13;309(15):883–887. doi: 10.1056/NEJM198310133091503. [DOI] [PubMed] [Google Scholar]
  2. Björkholm E., Pettersson F., Einhorn N., Krebs I., Nilsson B., Tjernberg B. Long-term follow-up and prognostic factors in ovarian carcinoma. The radiumhemmet series 1958 to 1973. Acta Radiol Oncol. 1982;21(6):413–419. doi: 10.3109/02841868209134321. [DOI] [PubMed] [Google Scholar]
  3. Cody M. M., Slevin M. L. Treatment decisions in advanced ovarian cancer. Br J Cancer. 1989 Aug;60(2):155–156. doi: 10.1038/bjc.1989.241. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Cunningham J. M., Francis G. E., Holland M. J., Pirollo K. F., Chang E. H. Aberrant DNA topoisomerase II activity, radioresistance and inherited susceptibility to cancer. Br J Cancer. 1991 Jan;63(1):29–36. doi: 10.1038/bjc.1991.8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Dembo A. J., Bush R. S. Current concepts in cancer: ovary--treatment of stages III and IV. Choice of postoperative therapy based on prognostic factors. Int J Radiat Oncol Biol Phys. 1982 May;8(5):893–897. doi: 10.1016/0360-3016(82)90096-7. [DOI] [PubMed] [Google Scholar]
  6. Dembo A. J., Davy M., Stenwig A. E., Berle E. J., Bush R. S., Kjorstad K. Prognostic factors in patients with stage I epithelial ovarian cancer. Obstet Gynecol. 1990 Feb;75(2):263–273. [PubMed] [Google Scholar]
  7. Gershenson D. M., Copeland L. J., Wharton J. T., Atkinson E. N., Sneige N., Edwards C. L., Rutledge F. N. Prognosis of surgically determined complete responders in advanced ovarian cancer. Cancer. 1985 Mar 1;55(5):1129–1135. doi: 10.1002/1097-0142(19850301)55:5<1129::aid-cncr2820550531>3.0.co;2-o. [DOI] [PubMed] [Google Scholar]
  8. Griffiths C. T. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr. 1975 Oct;42:101–104. [PubMed] [Google Scholar]
  9. Hawkins R. E., Roberts K., Wiltshaw E., Mundy J., Fryatt I. J., McCready V. R. The prognostic significance of the half-life of serum CA 125 in patients responding to chemotherapy for epithelial ovarian carcinoma. Br J Obstet Gynaecol. 1989 Dec;96(12):1395–1399. doi: 10.1111/j.1471-0528.1989.tb06301.x. [DOI] [PubMed] [Google Scholar]
  10. Jacobs I., Bast R. C., Jr The CA 125 tumour-associated antigen: a review of the literature. Hum Reprod. 1989 Jan;4(1):1–12. doi: 10.1093/oxfordjournals.humrep.a136832. [DOI] [PubMed] [Google Scholar]
  11. Lavin P. T., Knapp R. C., Malkasian G., Whitney C. W., Berek J. C., Bast R. C., Jr CA 125 for the monitoring of ovarian carcinoma during primary therapy. Obstet Gynecol. 1987 Feb;69(2):223–227. [PubMed] [Google Scholar]
  12. Marsoni S., Torri V., Valsecchi M. G., Belloni C., Bianchi U., Bolis G., Bonazzi C., Colombo N., Epis A., Favalli G. Prognostic factors in advanced epithelial ovarian cancer. (Gruppo Interregionale Cooperativo di Oncologia Ginecologica (GICOG)). Br J Cancer. 1990 Sep;62(3):444–450. doi: 10.1038/bjc.1990.315. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. McGuire W. L. Breast cancer prognostic factors: evaluation guidelines. J Natl Cancer Inst. 1991 Feb 6;83(3):154–155. doi: 10.1093/jnci/83.3.154. [DOI] [PubMed] [Google Scholar]
  14. Peto R., Pike M. C., Armitage P., Breslow N. E., Cox D. R., Howard S. V., Mantel N., McPherson K., Peto J., Smith P. G. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br J Cancer. 1977 Jan;35(1):1–39. doi: 10.1038/bjc.1977.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Redman C. W., Blackledge G. R., Kelly K., Powell J., Buxton E. J., Luesley D. M. Early serum CA125 response and outcome in epithelial ovarian cancer. Eur J Cancer. 1990;26(5):593–596. doi: 10.1016/0277-5379(90)90085-8. [DOI] [PubMed] [Google Scholar]
  16. Rees G. J. Cancer treatment: deciding what we can afford. BMJ. 1991 Apr 6;302(6780):799–800. doi: 10.1136/bmj.302.6780.799. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Rosen A., Sevelda P., Klein M., Spona J., Beck A. A CA125 score as a prognostic index in patients with ovarian cancer. Arch Gynecol Obstet. 1990;247(3):125–129. doi: 10.1007/BF02390860. [DOI] [PubMed] [Google Scholar]
  18. Rustin G. J., Gennings J. N., Nelstrop A. E., Covarrubias H., Lambert H. E., Bagshawe K. D. Use of CA-125 to predict survival of patients with ovarian carcinoma. North Thames Cooperative Group. J Clin Oncol. 1989 Nov;7(11):1667–1671. doi: 10.1200/JCO.1989.7.11.1667. [DOI] [PubMed] [Google Scholar]
  19. Rustin G. J. Impact of tumour marker measurements upon management of patients with carcinoma of the ovary. Dis Markers. 1991 May-Aug;9(3-4):153–158. [PubMed] [Google Scholar]
  20. Schray M., Martinez A., Cox R., Ballon S. Radiotherapy in epithelial ovarian cancer: analysis of prognostic factors based on long-term experience. Obstet Gynecol. 1983 Sep;62(3):373–382. [PubMed] [Google Scholar]
  21. Sevelda P., Schemper M., Spona J. CA 125 as an independent prognostic factor for survival in patients with epithelial ovarian cancer. Am J Obstet Gynecol. 1989 Nov;161(5):1213–1216. doi: 10.1016/0002-9378(89)90668-6. [DOI] [PubMed] [Google Scholar]
  22. Swenerton K. D., Hislop T. G., Spinelli J., LeRiche J. C., Yang N., Boyes D. A. Ovarian carcinoma: a multivariate analysis of prognostic factors. Obstet Gynecol. 1985 Feb;65(2):264–270. [PubMed] [Google Scholar]
  23. Vergote I. B., Børmer O. P., Abeler V. M. Evaluation of serum CA 125 levels in the monitoring of ovarian cancer. Am J Obstet Gynecol. 1987 Jul;157(1):88–92. doi: 10.1016/s0002-9378(87)80352-6. [DOI] [PubMed] [Google Scholar]
  24. Webb M. J. Cytoreduction in ovarian cancer: achievability and results. Baillieres Clin Obstet Gynaecol. 1989 Mar;3(1):83–94. doi: 10.1016/s0950-3552(89)80044-6. [DOI] [PubMed] [Google Scholar]
  25. Williams C. J. Implications of an overview of chemotherapy in advanced ovarian carcinoma. Br J Cancer. 1992 Aug;66(2):225–226. doi: 10.1038/bjc.1992.248. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. van der Burg M. E., Lammes F. B., van Putten W. L., Stoter G. Ovarian cancer: the prognostic value of the serum half-life of CA125 during induction chemotherapy. Gynecol Oncol. 1988 Jul;30(3):307–312. doi: 10.1016/0090-8258(88)90244-2. [DOI] [PubMed] [Google Scholar]
  27. van der Zee A. G., Duk J. M., Aalders J. G., Boontje A. H., ten Hoor K. A., de Bruijn H. W. The effect of abdominal surgery on the serum concentration of the tumour-associated antigen CA 125. Br J Obstet Gynaecol. 1990 Oct;97(10):934–938. doi: 10.1111/j.1471-0528.1990.tb02450.x. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES